Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Clinical trial NCT05186558 · UNKNOWN

Trial details

NCT number: NCT05186558
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type

Start date: 2022-05-15
Primary completion: 2024-01-15
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.